{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T01:50:07Z","timestamp":1775181007693,"version":"3.50.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Parkinson\u2019s disease (PD) is a chronic neurodegenerative condition that is characterized by motor symptoms as a result of dopaminergic degeneration, particularly in the mesostriatal pathway. However, in recent years, a greater number of clinical studies have focused on the emergence of non-motor symptoms in PD patients, as a consequence of damage on the mesolimbic and mesocortical dopaminergic networks, and on their significant impact on the quality of life of PD patients. Herein, we performed a thorough behavioral analysis including motor, emotional and cognitive dimensions, of the unilateral medial forebrain bundle (MFB) 6-hydroxidopamine (6-OHDA)-lesioned model of PD, and further addressed the impact of pharmacological interventions with levodopa and antidepressants on mood dimensions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Based on apomorphine-induced turning behaviour and degree of dopaminergic degeneration, animals submitted to MFB lesions were subdivided in complete and incomplete lesion groups. Importantly, this division also translated into a different severity of motor and exploratory impairments and depressive-like symptoms; in contrast, no deficits in anxiety-like and cognitive behaviors were found in MFB-lesioned animals. Subsequently, we found that the exploratory and the anhedonic behavioural alterations of MFB-lesioned rats can be partially improved with the administration of both levodopa or the antidepressant bupropion, but not paroxetine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results suggest that this model is a relevant tool to study the pathophysiology of motor and non-motor symptoms of PD. In addition, the present data shows that pharmacological interventions modulating dopaminergic transmission are also relevant to revert the non-motor behavioral deficits found in the disease.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1750-1326-8-14","type":"journal-article","created":{"date-parts":[[2013,4,26]],"date-time":"2013-04-26T12:15:08Z","timestamp":1366978508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":155,"title":["Behavioral characterization of the 6-hydroxidopamine model of Parkinson\u2019s disease and pharmacological rescuing of non-motor deficits"],"prefix":"10.1186","volume":"8","author":[{"given":"Miguel M","family":"Carvalho","sequence":"first","affiliation":[]},{"given":"Filipa L","family":"Campos","sequence":"additional","affiliation":[]},{"given":"B\u00e1rbara","family":"Coimbra","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 M","family":"P\u00eago","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Lima","sequence":"additional","affiliation":[]},{"given":"Ana J","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Nuno","family":"Sousa","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio J","family":"Salgado","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,4,26]]},"reference":[{"key":"393_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1176\/jnp.14.2.223","volume":"14","author":"J Parkinson","year":"2002","unstructured":"Parkinson J: An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002, 14: 223-236. 10.1176\/appi.neuropsych.14.2.223. discussion 222","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"393_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/0022-510X(73)90175-5","volume":"20","author":"H Bernheimer","year":"1973","unstructured":"Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F: Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973, 20: 415-455. 10.1016\/0022-510X(73)90175-5.","journal-title":"J Neurol Sci"},{"key":"393_CR3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","volume":"39","author":"W Dauer","year":"2003","unstructured":"Dauer W, Przedborski S: Parkinson\u2019s disease: mechanisms and models. Neuron. 2003, 39: 889-909. 10.1016\/S0896-6273(03)00568-3.","journal-title":"Neuron"},{"issue":"Pt 5","key":"393_CR4","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","volume":"114","author":"JM Fearnley","year":"1991","unstructured":"Fearnley JM, Lees AJ: Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity. Brain. 1991, 114 (Pt 5): 2283-2301.","journal-title":"Brain"},{"key":"393_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.tins.2007.03.006","volume":"30","author":"A Bjorklund","year":"2007","unstructured":"Bjorklund A, Dunnett SB: Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007, 30: 194-202. 10.1016\/j.tins.2007.03.006.","journal-title":"Trends Neurosci"},{"issue":"Suppl 2","key":"393_CR6","first-page":"S30","volume":"64","author":"JA Obeso","year":"2008","unstructured":"Obeso JA, Marin C, Rodriguez-Oroz C, Blesa J, Benitez-Temino B, Mena-Segovia J, Rodriguez M, Olanow CW: The basal ganglia in Parkinson\u2019s disease: current concepts and unexplained observations. Ann Neurol. 2008, 64 (Suppl 2): S30-46.","journal-title":"Ann Neurol"},{"key":"393_CR7","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J: Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008, 79: 368-376. 10.1136\/jnnp.2007.131045.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"393_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","volume":"5","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Healy DG, Schapira AH: Non-motor symptoms of Parkinson\u2019s disease: diagnosis and management. Lancet Neurol. 2006, 5: 235-245. 10.1016\/S1474-4422(06)70373-8.","journal-title":"Lancet Neurol"},{"key":"393_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF03159935","volume":"14","author":"KA Jellinger","year":"1991","unstructured":"Jellinger KA: Pathology of Parkinsons-Disease - changes other than the nigrostriatal pathway. Mol Chem Neuropathol. 1991, 14: 153-197. 10.1007\/BF03159935.","journal-title":"Mol Chem Neuropathol"},{"key":"393_CR10","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/0303-8467(92)90033-Y","volume":"94","author":"KA Jellinger","year":"1992","unstructured":"Jellinger KA, Paulus W: Clinicopathological correlations in Parkinsons-Disease. Clin Neurol Neurosurg. 1992, 94: S86-S88.","journal-title":"Clin Neurol Neurosurg"},{"key":"393_CR11","first-page":"293","volume":"19","author":"KS Price","year":"1978","unstructured":"Price KS, Farley IJ, Hornykiewicz O: Neurochemistry of Parkinson\u2019s disease: relation between striatal and limbic dopamine. Adv Biochem Psychopharmacol. 1978, 19: 293-300.","journal-title":"Adv Biochem Psychopharmacol"},{"key":"393_CR12","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/S0028-3932(02)00108-2","volume":"40","author":"V Czernecki","year":"2002","unstructured":"Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B: Motivation, reward, and Parkinson\u2019s disease: influence of dopatherapy. Neuropsychologia. 2002, 40: 2257-2267. 10.1016\/S0028-3932(02)00108-2.","journal-title":"Neuropsychologia"},{"key":"393_CR13","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1093\/brain\/awh445","volume":"128","author":"P Remy","year":"2005","unstructured":"Remy P, Doder M, Lees A, Turjanski N, Brooks D: Depression in Parkinson\u2019s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005, 128: 1314-1322. 10.1093\/brain\/awh445.","journal-title":"Brain"},{"key":"393_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/pmj.77.904.89","volume":"77","author":"K Walsh","year":"2001","unstructured":"Walsh K, Bennett G: Parkinson\u2019s disease and anxiety. Postgrad Med J. 2001, 77: 89-93. 10.1136\/pmj.77.904.89.","journal-title":"Postgrad Med J"},{"key":"393_CR15","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/mds.22586","volume":"24","author":"M Menza","year":"2009","unstructured":"Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A: The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson\u2019s disease. Mov Disord. 2009, 24: 1325-1332. 10.1002\/mds.22586.","journal-title":"Mov Disord"},{"key":"393_CR16","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/j.1532-5415.2004.52219.x","volume":"52","author":"D Weintraub","year":"2004","unstructured":"Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB: Effect of psychiatric and other nonmotor symptoms on disability in Parkinson\u2019s disease. J Am Geriatr Soc. 2004, 52: 784-788. 10.1111\/j.1532-5415.2004.52219.x.","journal-title":"J Am Geriatr Soc"},{"key":"393_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0014-2999(68)90164-7","volume":"5","author":"U Ungerstedt","year":"1968","unstructured":"Ungerstedt U: 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol. 1968, 5: 107-110. 10.1016\/0014-2999(68)90164-7.","journal-title":"Eur J Pharmacol"},{"key":"393_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/0006-8993(70)90187-3","volume":"24","author":"U Ungerstedt","year":"1970","unstructured":"Ungerstedt U, Arbuthnott GW: Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970, 24: 485-493. 10.1016\/0006-8993(70)90187-3.","journal-title":"Brain Res"},{"key":"393_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1006\/exnr.2002.7891","volume":"175","author":"R Deumens","year":"2002","unstructured":"Deumens R, Blokland A, Prickaerts J: Modeling Parkinson\u2019s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol. 2002, 175: 303-317. 10.1006\/exnr.2002.7891.","journal-title":"Exp Neurol"},{"key":"393_CR20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0306-4522(98)00217-6","volume":"88","author":"JW Chang","year":"1999","unstructured":"Chang JW, Wachtel SR, Young D, Kang UJ: Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson\u2019s disease: Studies on medial forebrain bundle and striatal lesions. Neuroscience. 1999, 88: 617-628. 10.1016\/S0306-4522(98)00217-6.","journal-title":"Neuroscience"},{"key":"393_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jneumeth.2006.06.001","volume":"158","author":"C Monville","year":"2006","unstructured":"Monville C, Torres EM, Dunnett SB: Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model. J Neurosci Methods. 2006, 158: 219-223. 10.1016\/j.jneumeth.2006.06.001.","journal-title":"J Neurosci Methods"},{"key":"393_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jneumeth.2004.10.004","volume":"144","author":"H Yuan","year":"2005","unstructured":"Yuan H, Sarre S, Ebinger G, Michotte Y: Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson\u2019s disease. J Neurosci Methods. 2005, 144: 35-45. 10.1016\/j.jneumeth.2004.10.004.","journal-title":"J Neurosci Methods"},{"key":"393_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0165-0270(91)90048-5","volume":"36","author":"CP Montoya","year":"1991","unstructured":"Montoya CP, Campbell-Hope LJ, Pemberton KD, Dunnett SB: The \u201cstaircase test\u201d: a measure of independent forelimb reaching and grasping abilities in rats. J Neurosci Methods. 1991, 36: 219-228. 10.1016\/0165-0270(91)90048-5.","journal-title":"J Neurosci Methods"},{"key":"393_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/0169-328X(96)00062-9","volume":"41","author":"HC Hung","year":"1996","unstructured":"Hung HC, Lee EHY: The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP(+) toxicity: Role of BDNF gene expression. Mol Brain Res. 1996, 41: 16-26. 10.1016\/0169-328X(96)00062-9.","journal-title":"Mol Brain Res"},{"key":"393_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1006\/exnr.2000.7624","volume":"169","author":"M Rodriguez","year":"2001","unstructured":"Rodriguez M, Barroso-Chinea P, Abdala P, Obeso J, Gonzalez-Hernandez T: Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in parkinson\u2019s disease. Exp Neurol. 2001, 169: 163-181. 10.1006\/exnr.2000.7624.","journal-title":"Exp Neurol"},{"key":"393_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbr.2005.11.026","volume":"169","author":"L Truong","year":"2006","unstructured":"Truong L, Allbutt H, Kassiou M, Henderson JM: Developing a preclinical model of Parkinson\u2019s disease: a study of behaviour in rats with graded 6-OHDA lesions. Behav Brain Res. 2006, 169: 1-9. 10.1016\/j.bbr.2005.11.026.","journal-title":"Behav Brain Res"},{"issue":"Suppl 2","key":"393_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1601-183X.2006.00228.x","volume":"5","author":"N Sousa","year":"2006","unstructured":"Sousa N, Almeida OF, Wotjak CT: A hitchhiker\u2019s guide to behavioral analysis in laboratory rodents. Genes Brain Behav. 2006, 5 (Suppl 2): 5-24.","journal-title":"Genes Brain Behav"},{"key":"393_CR28","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/cercor\/bhj043","volume":"16","author":"R Levy","year":"2006","unstructured":"Levy R, Dubois B: Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex. 2006, 16: 916-928.","journal-title":"Cereb Cortex"},{"key":"393_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0006-8993(80)90695-2","volume":"199","author":"JS Fink","year":"1980","unstructured":"Fink JS, Smith GP: Mesolimbicocortical dopamine terminal fields are necessary for normal locomotor and investigatory exploration in rats. Brain Res. 1980, 199: 359-384. 10.1016\/0006-8993(80)90695-2.","journal-title":"Brain Res"},{"key":"393_CR30","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/0091-3057(92)90422-C","volume":"43","author":"GH Jones","year":"1992","unstructured":"Jones GH, Robbins TW: Differential-Effects of Mesocortical, Mesolimbic, and Mesostriatal Dopamine Depletion on Spontaneous, Conditioned, and Drug-Induced Locomotor-Activity. Pharmacol Biochem Behav. 1992, 43: 887-895. 10.1016\/0091-3057(92)90422-C.","journal-title":"Pharmacol Biochem Behav"},{"key":"393_CR31","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0301-0082(98)00041-0","volume":"56","author":"W Hauber","year":"1998","unstructured":"Hauber W: Involvement of basal ganglia transmitter systems in movement initiation. Prog Neurobiol. 1998, 56: 507-540. 10.1016\/S0301-0082(98)00041-0.","journal-title":"Prog Neurobiol"},{"key":"393_CR32","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/mds.22833","volume":"25","author":"NNW Dissanayaka","year":"2010","unstructured":"Dissanayaka NNW, Sellbach A, Matheson S, O\u2019Sullivan JD, Silburn PA, Byrne GJ, Marsh R, Mellick GD: Anxiety Disorders in Parkinson's Disease: Prevalence and Risk Factors. Mov Disord. 2010, 25: 838-845. 10.1002\/mds.22833.","journal-title":"Mov Disord"},{"key":"393_CR33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.neuroscience.2012.05.052","volume":"218","author":"KLE Eskow Jaunarajs","year":"2012","unstructured":"Eskow Jaunarajs KLE, George JA, Bishop C: L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson\u2019s disease. Neuroscience. 2012, 218: 243-256.","journal-title":"Neuroscience"},{"key":"393_CR34","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1002\/jnr.21642","volume":"86","author":"I Branchi","year":"2008","unstructured":"Branchi I, D\u2019Andrea I, Armida M, Cassano T, P\u00e8zzola A, Potenza RL, Morgese MG, Popoli P, Alleva E: Nonmotor symptoms in Parkinson\u2019s disease: Investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J Neurosci Res. 2008, 86: 2050-2061. 10.1002\/jnr.21642.","journal-title":"J Neurosci Res"},{"key":"393_CR35","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/FBP.0b013e32833e7e80","volume":"21","author":"KLE Eskow Jaunarajs","year":"2010","unstructured":"Eskow Jaunarajs KLE, Dupre KB, Ostock CY, Button T, Deak T, Bishop C: Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat. Behav Pharmacol. 2010, 21: 627-637. 10.1097\/FBP.0b013e32833e7e80.","journal-title":"Behav Pharmacol"},{"key":"393_CR36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.bbr.2010.07.023","volume":"216","author":"J Jungnickel","year":"2011","unstructured":"Jungnickel J, Kalve L, Reimers L, Nobre A, Wesemann M, Ratzka A, Halfer N, Lindemann C, Schwabe K, Tollner K: Topology of intrastriatal dopaminergic grafts determines functional and emotional outcome in neurotoxin-lesioned rats. Behav Brain Res. 2011, 216: 129-135. 10.1016\/j.bbr.2010.07.023.","journal-title":"Behav Brain Res"},{"key":"393_CR37","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.neuroscience.2008.08.035","volume":"156","author":"MT Tadaiesky","year":"2008","unstructured":"Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, Takahashi RN: Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson\u2019s disease. Neuroscience. 2008, 156: 830-840. 10.1016\/j.neuroscience.2008.08.035.","journal-title":"Neuroscience"},{"key":"393_CR38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/mds.21803","volume":"23","author":"JS Reijnders","year":"2008","unstructured":"Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF: A systematic review of prevalence studies of depression in Parkinson\u2019s disease. Mov Disord. 2008, 23: 183-189. 10.1002\/mds.21803. quiz 313","journal-title":"Mov Disord"},{"key":"393_CR39","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.biopsych.2005.09.018","volume":"59","author":"EJ Nestler","year":"2006","unstructured":"Nestler EJ, Carlezon WA: The mesolimbic dopamine reward circuit in depression. Biol Psychiatry. 2006, 59: 1151-1159. 10.1016\/j.biopsych.2005.09.018.","journal-title":"Biol Psychiatry"},{"key":"393_CR40","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1600-0404.2006.00579.x","volume":"113","author":"L Ishihara","year":"2006","unstructured":"Ishihara L, Brayne C: A systematic review of depression and mental illness preceding Parkinson\u2019s disease. Acta Neurol Scand. 2006, 113: 211-220. 10.1111\/j.1600-0404.2006.00579.x.","journal-title":"Acta Neurol Scand"},{"key":"393_CR41","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.euroneuro.2006.04.006","volume":"17","author":"F Chenu","year":"2007","unstructured":"Chenu F, Dailly E, Bourin M: Effect of antidepressant drugs on 6-OHDA-treated mice in the FST. Eur Neuropsychopharmacol. 2007, 17: 187-193. 10.1016\/j.euroneuro.2006.04.006.","journal-title":"Eur Neuropsychopharmacol"},{"key":"393_CR42","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.pnpbp.2010.06.004","volume":"34","author":"RM Santiago","year":"2010","unstructured":"Santiago RM, Barbieiro J, Lima MMS, Dombrowski PA, Andreatini R, Vital MABF: Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson\u2019s disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry. 2010, 34: 1104-1114. 10.1016\/j.pnpbp.2010.06.004.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"393_CR43","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bbr.2007.07.002","volume":"184","author":"C Winter","year":"2007","unstructured":"Winter C, von Rumohr A, Mundt A, Petrus D, Klein J, Lee T, Morgenstern R, Kupsch A, Juckel G: Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Behav Brain Res. 2007, 184: 133-141. 10.1016\/j.bbr.2007.07.002.","journal-title":"Behav Brain Res"},{"key":"393_CR44","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00213-011-2356-7","volume":"218","author":"XQ Zhang","year":"2011","unstructured":"Zhang XQ, Egeland M, Svenningsson P: Antidepressant-like properties of sarizotan in experimental Parkinsonism. Psychopharmacology. 2011, 218: 621-634. 10.1007\/s00213-011-2356-7.","journal-title":"Psychopharmacology"},{"key":"393_CR45","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0166-4328(01)00461-2","volume":"134","author":"T Shimura","year":"2002","unstructured":"Shimura T, Kamada Y, Yamamoto T: Ventral tegmental lesions reduce overconsumption of normally preferred taste fluid in rats. Behav Brain Res. 2002, 134: 123-130. 10.1016\/S0166-4328(01)00461-2.","journal-title":"Behav Brain Res"},{"key":"393_CR46","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S1734-1140(11)70702-2","volume":"63","author":"K Kuter","year":"2011","unstructured":"Kuter K, Kolasiewicz W, Golembiowska K, Dziubina A, Schulze G, Berghauzen K, Wardas J, Ossowska K: Partial lesion of the dopaminergic innervation of the ventral striatum induces \u201cdepressive-like\u201d behavior of rats. Pharmacol Rep. 2011, 63: 1383-1392.","journal-title":"Pharmacol Rep"},{"key":"393_CR47","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1523\/JNEUROSCI.23-15-06351.2003","volume":"23","author":"SJ Lewis","year":"2003","unstructured":"Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM: Cognitive impairments in early Parkinson\u2019s disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci. 2003, 23: 6351-6356.","journal-title":"J Neurosci"},{"key":"393_CR48","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1016\/j.neuropsychologia.2008.07.011","volume":"46","author":"AA Moustafa","year":"2008","unstructured":"Moustafa AA, Sherman SJ, Frank MJ: A dopaminergic basis for working memory, learning and attentional shifting in Parkinsonism. Neuropsychologia. 2008, 46: 3144-3156. 10.1016\/j.neuropsychologia.2008.07.011.","journal-title":"Neuropsychologia"},{"issue":"Pt 6","key":"393_CR49","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1093\/brain\/115.6.1727","volume":"115","author":"AM Owen","year":"1992","unstructured":"Owen AM, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, Lange KW, Robbins TW: Fronto-striatal cognitive deficits at different stages of Parkinson\u2019s disease. Brain. 1992, 115 (Pt 6): 1727-1751.","journal-title":"Brain"},{"key":"393_CR50","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1460-9568.1996.tb01219.x","volume":"8","author":"AM Owen","year":"1996","unstructured":"Owen AM, Doyon J, Petrides M, Evans AC: Planning and spatial working memory: a positron emission tomography study in humans. Eur J Neurosci. 1996, 8: 353-364. 10.1111\/j.1460-9568.1996.tb01219.x.","journal-title":"Eur J Neurosci"},{"key":"393_CR51","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00213-007-0862-4","volume":"194","author":"E De Leonibus","year":"2007","unstructured":"De Leonibus E, Pascucci T, Lopez S, Oliverio A, Amalric M, Mele A: Spatial deficits in a mouse model of Parkinson disease. Psychopharmacology. 2007, 194: 517-525. 10.1007\/s00213-007-0862-4.","journal-title":"Psychopharmacology"},{"key":"393_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0166-4328(01)00211-X","volume":"124","author":"C Da Cunha","year":"2001","unstructured":"Da Cunha C, Gevaerd MS, Vital MABF, Miyoshi E, Andreatini R, Silveira R, Takahashi RN, Canteras NS: Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson\u2019s disease amnesia. Behav Brain Res. 2001, 124: 9-18. 10.1016\/S0166-4328(01)00211-X.","journal-title":"Behav Brain Res"},{"key":"393_CR53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0166-4328(85)90165-2","volume":"18","author":"IQ Whishaw","year":"1985","unstructured":"Whishaw IQ, Dunnett SB: Dopamine depletion, stimulation or blockade in the rat disrupts spatial navigation and locomotion dependent upon beacon or distal cues. Behav Brain Res. 1985, 18: 11-29. 10.1016\/0166-4328(85)90165-2.","journal-title":"Behav Brain Res"},{"key":"393_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0166-4328(98)00160-0","volume":"102","author":"MD Lindner","year":"1999","unstructured":"Lindner MD, Cain CK, Plone MA, Frydel BR, Blaney TJ, Emerich DF, Hoane MR: Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behav Brain Res. 1999, 102: 1-16. 10.1016\/S0166-4328(98)00160-0.","journal-title":"Behav Brain Res"},{"key":"393_CR55","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jneumeth.2005.04.005","volume":"148","author":"MM Ferro","year":"2005","unstructured":"Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci MEM, Canteras NS, Da Cunha C: Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson\u2019s disease: Histological, neurochemical, motor and memory alterations. J Neurosci Methods. 2005, 148: 78-87. 10.1016\/j.jneumeth.2005.04.005.","journal-title":"J Neurosci Methods"},{"key":"393_CR56","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/mds.10472","volume":"18","author":"A Mura","year":"2003","unstructured":"Mura A, Feldon J: Spatial learning in rats is impaired after degeneration of the nigrostriatal dopaminergic system. Movement Dis. 2003, 18: 860-871. 10.1002\/mds.10472.","journal-title":"Movement Dis"},{"key":"393_CR57","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.pnpbp.2009.09.023","volume":"34","author":"MA Stacy","year":"2010","unstructured":"Stacy MA, Murck H, Kroenke K: Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy. Prog Neuro-Psychopharmacol Biolog Psychiat. 2010, 34: 57-61. 10.1016\/j.pnpbp.2009.09.023.","journal-title":"Prog Neuro-Psychopharmacol Biolog Psychiat"},{"key":"393_CR58","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/jnnp.66.4.541","volume":"66","author":"V Fetoni","year":"1999","unstructured":"Fetoni V, Soliveri P, Monza D, Testa D, Girotti F: Affective symptoms in multiple system atrophy and Parkinson\u2019s disease: response to levodopa therapy. J Neurol Neurosurg Psychiat. 1999, 66: 541-544. 10.1136\/jnnp.66.4.541.","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"393_CR59","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/mds.10441","volume":"18","author":"A Funkiewiez","year":"2003","unstructured":"Funkiewiez A, Ardouin C, Krack P, Fraix V, Van Blercom N, Xie J, Moro E, Benabid AL, Pollak P: Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson\u2019s disease. Movement Dis. 2003, 18: 524-530. 10.1002\/mds.10441.","journal-title":"Movement Dis"},{"key":"393_CR60","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1212\/WNL.45.9.1757","volume":"45","author":"RA Maricle","year":"1995","unstructured":"Maricle RA, Nutt JG, Valentine RJ, Carter JH: Dose\u2013response Relationship of Levodopa with Mood and Anxiety in Fluctuating Parkinsons-Disease - a Double-Blind, Placebo-Controlled Study. Neurology. 1995, 45: 1757-1760. 10.1212\/WNL.45.9.1757.","journal-title":"Neurology"},{"key":"393_CR61","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/brain\/awf052","volume":"125","author":"R Cools","year":"2002","unstructured":"Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM: Dopaminergic modulation of high-level cognition in Parkinson\u2019s disease: the role of the prefrontal cortex revealed by PET. Brain. 2002, 125: 584-594. 10.1093\/brain\/awf052.","journal-title":"Brain"},{"key":"393_CR62","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.bbr.2010.03.023","volume":"211","author":"A Santamaria","year":"2010","unstructured":"Santamaria A, Arias HR: Neurochemical and behavioral effects elicited by bupropion and diethylpropion in rats. Behav Brain Res. 2010, 211: 132-139. 10.1016\/j.bbr.2010.03.023.","journal-title":"Behav Brain Res"},{"key":"393_CR63","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.physbeh.2007.01.003","volume":"90","author":"JL Wilkinson","year":"2007","unstructured":"Wilkinson JL, Bevins RA: Bupropion hydrochloride produces conditioned hyperactivity in rats. Physiol Behav. 2007, 90: 790-796. 10.1016\/j.physbeh.2007.01.003.","journal-title":"Physiol Behav"},{"key":"393_CR64","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.pbb.2012.08.012","volume":"103","author":"K Socala","year":"2012","unstructured":"Socala K, Nieoczym D, Wyska E, Poleszak E, Wlaz P: Influence of sildenafil on the antidepressant activity of bupropion and venlafaxine in the forced swim test in mice. Pharmacol Biochem Behav. 2012, 103: 273-278. 10.1016\/j.pbb.2012.08.012.","journal-title":"Pharmacol Biochem Behav"},{"key":"393_CR65","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-3565(25)32266-4","volume":"215","author":"BR Cooper","year":"1980","unstructured":"Cooper BR, Hester TJ, Maxwell RA: Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther. 1980, 215: 127-134.","journal-title":"J Pharmacol Exp Ther"},{"key":"393_CR66","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/sj.bjp.0707151","volume":"150","author":"P Bredeloux","year":"2007","unstructured":"Bredeloux P, Dubuc I, Costentin J: Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission. Br J Pharmacol. 2007, 150: 711-719. 10.1038\/sj.bjp.0707151.","journal-title":"Br J Pharmacol"},{"key":"393_CR67","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00210-010-0521-x","volume":"382","author":"Y Kitamura","year":"2010","unstructured":"Kitamura Y, Yagi T, Kitagawa K, Shinomiya K, Kawasaki H, Asanuma M, Gomita Y: Effects of bupropion on the forced swim test and release of dopamine in the nucleus accumbens in ACTH-treated rats. N-S Arch Pharmacol. 2010, 382: 151-158. 10.1007\/s00210-010-0521-x.","journal-title":"N-S Arch Pharmacol"},{"key":"393_CR68","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1017\/S1041610210001687","volume":"23","author":"M Zaluska","year":"2011","unstructured":"Zaluska M, Dyduch A: Bupropion in the treatment of depression in Parkinson\u2019s disease. Int Psychogeriatrics\/IPA. 2011, 23: 325-327. 10.1017\/S1041610210001687.","journal-title":"Int Psychogeriatrics\/IPA"},{"key":"393_CR69","first-page":"2157","volume":"144","author":"AF Leentjens","year":"2000","unstructured":"Leentjens AF, Verhey FR, Vreeling FW: Successful treatment of depression in a Parkinson disease patient with bupropion. Ned Tijdschr Geneeskd. 2000, 144: 2157-2159.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"393_CR70","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00702-005-0368-3","volume":"113","author":"B Scholtissen","year":"2006","unstructured":"Scholtissen B, Verhey FR, Steinbusch HW, Leentjens AF: Serotonergic mechanisms in Parkinson\u2019s disease: opposing results from preclinical and clinical data. J Neural Transm. 2006, 113: 59-73. 10.1007\/s00702-005-0368-3.","journal-title":"J Neural Transm"},{"key":"393_CR71","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1212\/WNL.0b013e3182516244","volume":"78","author":"IH Richard","year":"2012","unstructured":"Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M: A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012, 78: 1229-1236. 10.1212\/WNL.0b013e3182516244.","journal-title":"Neurology"},{"key":"393_CR72","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","volume":"72","author":"M Menza","year":"2009","unstructured":"Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A: A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009, 72: 886-892. 10.1212\/01.wnl.0000336340.89821.b3.","journal-title":"Neurology"},{"key":"393_CR73","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.pnpbp.2004.11.023","volume":"29","author":"H Takahashi","year":"2005","unstructured":"Takahashi H, Kamata M, Yoshida K, Higuchi H, Shimizu T: Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson\u2019s disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports. Prog Neuro-Psychopharmacol Biolog Psychiat. 2005, 29: 351-353. 10.1016\/j.pnpbp.2004.11.023.","journal-title":"Prog Neuro-Psychopharmacol Biolog Psychiat"},{"key":"393_CR74","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.nbd.2011.01.024","volume":"42","author":"V Francardo","year":"2011","unstructured":"Francardo V, Recchia A, Popovic N, Andersson D, Nissbrandt H, Cenci MA: Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson\u2019s disease. Neurobiol Disease. 2011, 42: 327-340. 10.1016\/j.nbd.2011.01.024.","journal-title":"Neurobiol Disease"},{"key":"393_CR75","volume-title":"The Rat Brain in Stereotaxic Coordinates","author":"G Paxinos","year":"1998","unstructured":"Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. 1998, San Diego, USA: Academic, 4","edition":"4"},{"key":"393_CR76","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.pain.2009.02.024","volume":"144","author":"H Leite-Almeida","year":"2009","unstructured":"Leite-Almeida H, Almeida-Torres L, Mesquita AR, Pertovaara A, Sousa N, Cerqueira JJ, Almeida A: The impact of age on emotional and cognitive behaviours triggered by experimental neuropathy in rats. Pain. 2009, 144: 57-65. 10.1016\/j.pain.2009.02.024.","journal-title":"Pain"},{"key":"393_CR77","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.bbr.2006.06.035","volume":"173","author":"JM Pego","year":"2006","unstructured":"Pego JM, Morgado P, Cerqueira JJ, Almeida OFX, Sousa N: Mismatch between anxiety status and morphometric parameters in the amygdala and bed nucleus of the stria terminalis. Behav Brain Res. 2006, 173: 320-325. 10.1016\/j.bbr.2006.06.035.","journal-title":"Behav Brain Res"},{"key":"393_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/neuro.08.001.2009","volume":"3","author":"JM Bessa","year":"2009","unstructured":"Bessa JM, Mesquita AR, Oliveira M, Pego JM, Cerqueira JJ, Palha JA, Almeida OF, Sousa N: A trans-dimensional approach to the behavioral aspects of depression. Front Behav Neurosci. 2009, 3: 1-","journal-title":"Front Behav Neurosci"},{"key":"393_CR79","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1523\/JNEUROSCI.4372-06.2007","volume":"27","author":"JJ Cerqueira","year":"2007","unstructured":"Cerqueira JJ, Mailliet F, Almeida OFX, Jay TM, Sousa N: The prefrontal cortex as a key target of the maladaptive response to stress. J Neurosci. 2007, 27: 2781-2787. 10.1523\/JNEUROSCI.4372-06.2007.","journal-title":"J Neurosci"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1750-1326-8-14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T06:39:58Z","timestamp":1745995198000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/1750-1326-8-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,26]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["393"],"URL":"https:\/\/doi.org\/10.1186\/1750-1326-8-14","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,26]]},"assertion":[{"value":"29 January 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"14"}}